4basebio PLC (LON:4BB – Get Free Report) insider Amy Walker bought 1,863 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of GBX 509 per share, for a total transaction of £9,482.67.
4basebio Stock Performance
4BB stock opened at GBX 509 on Friday. The stock has a 50-day moving average price of GBX 496.71 and a 200-day moving average price of GBX 579.35. 4basebio PLC has a 1-year low of GBX 420 and a 1-year high of GBX 1,150. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The firm has a market cap of £78.82 million, a PE ratio of -5.14 and a beta of 1.09.
4basebio (LON:4BB – Get Free Report) last posted its quarterly earnings data on Wednesday, May 20th. The company reported GBX (1.09) earnings per share for the quarter. The firm had revenue of GBX 169 million during the quarter. As a group, equities research analysts expect that 4basebio PLC will post -3.43 earnings per share for the current year.
4basebio Company Profile
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.
Recommended Stories
- Five stocks we like better than 4basebio
- Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
- Intuit’s Great SaaS Reset: Fired By AI
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.
